Stella Diagnostics (Stella Diagnostics) Cash Flow from Others : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Cash Flow from Others?

Stella Diagnostics's cash flow from others for the three months ended in Sep. 2023 was $0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Stella Diagnostics Cash Flow from Others Historical Data

The historical data trend for Stella Diagnostics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Cash Flow from Others Chart

Stella Diagnostics Annual Data

Trend

Cash Flow from Others

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Cash Flow from Others	-	-

Stella Diagnostics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Stella Diagnostics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.